Xipamide: no advantage over bendrofluazide in hypertension.
作者信息
Ramsay L E, Freestone S
出版信息
Br J Clin Pharmacol. 1984 Oct;18(4):616-8. doi: 10.1111/j.1365-2125.1984.tb02514.x.
Abstract
In patients with uncontrolled hypertension addition of xipamide 20 mg daily to bendrofluazide 5 mg daily produced no significant additive antihypertensive effect, and the 95% confidence limits excluded a clinically important response. Xipamide treatment worsened hypokalaemia and increased the blood urea concentration significantly.
摘要
相似文献
1
Xipamide: no advantage over bendrofluazide in hypertension.
Br J Clin Pharmacol. 1984 Oct;18(4):616-8. doi: 10.1111/j.1365-2125.1984.tb02514.x.
2
Comparison of the hypotensive effects of bendrofluazide, bumetanide and xipamide.
Curr Med Res Opin. 1983;8(9):645-8. doi: 10.1185/03007998309109813.
3
Studies covering combined treatments with xipamide. Results of a long-term antihypertensive treatment.
Int J Clin Pharmacol Biopharm. 1977 Jun;15(6):260-6.
4
Once daily administration of low-dose xipamide: a long-term study in mild to moderate hypertension.
Int J Clin Pharmacol Ther Toxicol. 1983 Aug;21(8):394-8.
5
Clinical trial of xipamide in the treatment of hypertension.
J Int Med Res. 1980;8(1):38-43. doi: 10.1177/030006058000800107.
6
A log-dose-response study of xipamide and its effect on metabolic parameters.
J Hypertens Suppl. 1989 Dec;7(6):S320-1. doi: 10.1097/00004872-198900076-00156.
7
Xipamide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.
Drugs. 1985 Oct;30(4):313-32. doi: 10.2165/00003495-198530040-00002.
8
Nadolol in combination with indapamide and xipamide in resistant hypertensives.
Eur J Clin Pharmacol. 1985;28(1):29-33. doi: 10.1007/BF00635704.
9
Comparison of two combined diuretics in the treatment of essential hypertension.
Int J Clin Pharmacol Ther Toxicol. 1989 Jul;27(7):342-5.
10
Comparison of the antihypertensive activities of xipamide and chlorthalidone: a double-blind, randomized, crossover trial.
Curr Med Res Opin. 1981;7(4):247-52. doi: 10.1185/03007998109114270.
引用本文的文献
1
Identification of AURKA as a Biomarker Associated with Cuproptosis and Ferroptosis in HNSCC.
Int J Mol Sci. 2024 Apr 16;25(8):4372. doi: 10.3390/ijms25084372.
2
Analyzing the characteristics of immune cell infiltration in lung adenocarcinoma via bioinformatics to predict the effect of immunotherapy.
Immunogenetics. 2021 Oct;73(5):369-380. doi: 10.1007/s00251-021-01223-8. Epub 2021 Jul 24.
3
Xipamide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.
Drugs. 1985 Oct;30(4):313-32. doi: 10.2165/00003495-198530040-00002.
本文引用的文献
1
A study of the antihypertensive action of xipamide using ambulatory intra-arterial monitoring.
Br J Clin Pharmacol. 1981 Sep;12(3):381-5. doi: 10.1111/j.1365-2125.1981.tb01230.x.
2
Sample size for short-term trials of antihypertensive drugs.
Br J Clin Pharmacol. 1982 Aug;14(2):265-8. doi: 10.1111/j.1365-2125.1982.tb01971.x.
3
Xipamide and cyclopenthiazide in essential hypertension--comparative effects on blood pressure and plasma potassium.
Br J Clin Pharmacol. 1982 Jun;13(6):859-63. doi: 10.1111/j.1365-2125.1982.tb01879.x.
4
Comparison of the antihypertensive activities of xipamide and chlorthalidone: a double-blind, randomized, crossover trial.
Curr Med Res Opin. 1981;7(4):247-52. doi: 10.1185/03007998109114270.
5
"Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic.
Br Med J (Clin Res Ed). 1984 Jan 14;288(6411):106-11. doi: 10.1136/bmj.288.6411.106.
6
[Pharmacological and toxicological properties of the saluretic xipamide (4-chloro-5-sulfamoyl-2',6'-salicyloxylidide)].
Arzneimittelforschung. 1975 Feb;25(2):245-51.
7
Evaluation of beta blockade bendrofluazide, and prazosin in severe hypertension.
Lancet. 1977 Feb 5;1(8006):271-4. doi: 10.1016/s0140-6736(77)91822-0.
Zotero 插件